These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32242472)

  • 1. Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus.
    Mboumba Bouassa RS; Péré H; Jenabian MA; Veyer D; Meye JF; Touzé A; Bélec L
    Expert Rev Anti Infect Ther; 2020 Jun; 18(6):579-607. PubMed ID: 32242472
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.
    Wang X; Che Y; Chen B; Zhang Y; Nakagawa M; Wang X
    Int Immunopharmacol; 2018 Mar; 56():249-260. PubMed ID: 29414659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.
    Garbuglia AR; Lapa D; Sias C; Capobianchi MR; Del Porto P
    Front Immunol; 2020; 11():188. PubMed ID: 32133000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.
    Jiang RT; Wang JW; Peng S; Huang TC; Wang C; Cannella F; Chang YN; Viscidi RP; Best SRA; Hung CF; Roden RBS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28515303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to oncogenic human papillomaviruses.
    Konya J; Dillner J
    Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
    Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
    Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducing Immunity Where It Matters: Orthotopic HPV Tumor Models and Therapeutic Vaccinations.
    Zottnick S; Voß AL; Riemer AB
    Front Immunol; 2020; 11():1750. PubMed ID: 32922389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.
    Pattyn J; Van Keer S; Tjalma W; Matheeussen V; Van Damme P; Vorsters A
    Papillomavirus Res; 2019 Dec; 8():100185. PubMed ID: 31494291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine.
    Gupta G; Giannino V; Rishi N; Glueck R
    Vaccine; 2016 Sep; 34(39):4724-4731. PubMed ID: 27523740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines and immunization against human papillomavirus.
    Christensen ND; Budgeon LR
    Curr Probl Dermatol; 2014; 45():252-64. PubMed ID: 24643192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.